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Patients with acute kidney injury frequently have pulmonary
complications. Similarly ischemic acute kidney injury
or bilateral nephrectomy in rodents causes lung injury
characterized by pulmonary edema, increased pulmonary
capillary leak and interstitial leukocyte infiltration.
Interleukin-6 is a pro-inflammatory cytokine that is increased
in the serum of patients with acute kidney injury and predicts
mortality. Here we found that lung neutrophil infiltration,
myeloperoxidase activity, the neutrophil chemokines KC and
MIP-2 and capillary leak all increased within 4 h following
acute kidney injury in wild-type mice. These pathologic
factors were reduced in interleukin-6-deficient mice following
acute kidney injury or bilateral nephrectomy. The lungs of
mutant mice had reduced KC but MIP-2 was similar to that of
wild type mice. Wild-type mice, treated with an interleukin-6
inactivating antibody, had decreased lung myeloperoxidase
activity and KC levels following acute kidney injury. Our study
shows that interleukin-6 contributes to lung injury following
acute kidney injury.
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Acute kidney injury (AKI) is associated with an increased
incidence of respiratory failure requiring mechanical venti-
lation, which greatly increases mortality.1–4 The cause of
respiratory failure in patients with AKI is incompletely
understood. Using rodent models, we and others have
previously demonstrated that lung injury occurs following
ischemic AKI.5–11 Approximately 50% of AKI in hospitalized
patients is caused by renal ischemia;12 therefore, under-
standing the remote organ effects of ischemic AKI is clinically
relevant. However, lung injury also occurs after ischemia–
reperfusion injury of other organs such as the liver, gut, and
hind limb.13–17 Bilateral nephrectomy is increasingly being
utilized to isolate the effects of renal failure (for example,
impaired clearance and metabolism) from those of renal
ischemia; significant lung injury following bilateral nephrect-
omy has been reported by our group and others.5,10,18
Interestingly, pulmonary edema, increased pulmonary capil-
lary leak, and increased interstitial leukocytes are hallmarks
of lung injury after bilateral nephrectomy as well as after
ischemic AKI. In this study, we sought to identify facilitators
of AKI-mediated lung injury using these two different models
of AKI.
We have demonstrated previously that serum IL-6
increases after ischemic AKI and bilateral nephrectomy in
mice.5 In patients with AKI, IL-6 is significantly increased
and is predictive of mortality.19 Likewise, in patients with
acute lung injury (ALI), circulating IL-6 is elevated and
predicts mortality.20,21 Impaired neutrophil migration in
IL-6-deficient mice has been described in infectious and
noninfectious models of lung inflammation.22–24 Given this
background, we hypothesized that circulating IL-6 plays a
role in lung injury following AKI. Using methods to inhibit
IL-6, we demonstrate that IL-6 contributes to lung injury
following ischemic AKI and bilateral nephrectomy.
RESULTS
Lung myeloperoxidase activity after AKI
To determine the time course of lung injury after ischemic
AKI and bilateral nephrectomy, myeloperoxidase (MPO)
activity was measured in lung tissue from wild-type mice
at baseline and at 1, 2, 4, and 24 h after sham operation,
ischemic AKI, or bilateral nephrectomy. MPO activity
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significantly increased after ischemic AKI and bilateral
nephrectomy compared with sham operation at all time
points, peaking at 4 h (Figure 1a). MPO, the most abundant
protein in neutrophils, is released by activated neutrophils
after entry into sites of inflammation and is a key component
of their microbicidal activity. MPO activity is widely used as
a biochemical marker for tissue neutrophil content. Mono-
cytes may contain a small amount of MPO due to synthesis
or uptake of neutrophil-derived MPO.25 MPO may have
direct deleterious pulmonary effects, as severe acute lung
injury resulting from intratracheal administration of MPO
has been reported.26
Lung chemokines and adhesion molecules after AKI
To examine potential mediators of lung neutrophil recruit-
ment, the neutrophil chemokines keritinocyte-derived
chemokine (KC) (CXCL1) and macrophage inflammatory
protein-2 (MIP-2) (CXCL2) were measured by ELISA in lung
tissue of wild-type mice at baseline and at 1, 2, 4, and 24 h
after sham operation, ischemic AKI, or bilateral nephrec-
tomy. As shown in Figure 1b and c, both lung KC and
MIP-2 increased at 2 and 4 h after ischemic AKI and bilateral
nephrectomy compared with sham operation.
To further investigate potential mediators of lung
neutrophil recruitment, immunoblotting for the adhesion
molecules intercellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) was performed
in lung tissue obtained from wild-type mice at baseline and
at 1, 2, 4, and 24 h after sham operation, ischemic AKI, or
bilateral nephrectomy. Both ICAM-1 and VCAM-1 were
present in the lung at all time points after sham operation,
ischemic AKI, and bilateral nephrectomy; however, expres-
sion was similar to that observed at baseline (no surgery)
(Figure 2a and b). In addition, expression of lung ICAM-1
and VCAM-1 did not vary among the different time points in
all surgical groups (data not shown). Equal protein loading
was verified by membrane staining for all immunoblots
(not shown).
Lung histology after AKI
To determine whether peak MPO activity 4 h after AKI
corresponded to an increase in lung neutrophil recruitment
and lung injury, lung histology was examined 4 h after sham
operation, ischemic AKI, and bilateral nephrectomy. In
contrast to the normal lung histology seen after sham
operation, pulmonary histology after ischemic AKI and
bilateral nephrectomy was characterized by increased vas-
cular congestion, septal edema, and neutrophil infiltration
(Figure 3). Interstitial neutrophil counts (per 50 high
powered fields, 40 original magnification) were 17±4 in
sham, 98±13 in ischemic AKI, and 150±38 in bilateral
nephrectomy (Po0.05 ischemic AKI vs sham, Po0.05
bilateral nephrectomy vs sham, P¼NS ischemic AKI vs
bilateral nephrectomy, N¼ 3).
Pulmonary capillary leak after AKI
To determine whether increased lung MPO activity and lung
neutrophil infiltration observed 4 h after ischemic AKI and
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Figure 1 | Lung MPO activity, KC, and MIP-2 after ischemic AKI
and bilateral nephrectomy. MPO activity (a marker for
neutrophils) and KC and MIP-2 (neutrophil chemokines) were
measured in lung tissue of wild-type mice at baseline and at
1, 2, 4, and 24 h after sham operation (Sham), ischemic AKI (IAKI),
and bilateral nephrectomy (BNx). (a) MPO activity significantly
increased at 1, 2, 4, and 24 h following IAKI and BNx compared
with sham operation (N¼ 3–11). Chemokines (b) KC and (c) MIP-2
significantly increased at 2 and 4 h following IAKI and BNx
compared with sham operation as measured by ELISA (N¼ 3–9).
*Po0.05 IAKI vs Sham, **Po0.01 IAKI vs Sham, ***Po0.001 IAKI vs
Sham, wPo0.05 BNx vs Sham, wwPo0.01 BNx vs Sham.
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Figure 2 | Lung adhesion molecules after ischemic AKI and
bilateral nephrectomy. Immunoblotting for the adhesion
molecules ICAM-1 and VCAM-1 in lung tissue was performed at
baseline and at 1, 2, 4, and 24 h after sham operation (Sham),
ischemic AKI (IAKI), and bilateral nephrectomy (BNx). Both lung
(a) ICAM-1 and (b) VCAM-1 were detected at baseline and at 4 h
after sham operation, ischemic AKI, and bilateral nephrectomy; no
detectable differences were observed among groups.
Immunoblots are representative of at least three separate
experiments.
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bilateral nephrectomy was associated with increased capillary
leak, lung content of Evans blue dye (EBD) was determined
at baseline and at 4 h after sham operation, ischemic AKI,
and bilateral nephrectomy in wild-type mice. EBD was
administered via tail vein injection, and lung EBD content
was determined as an indicator of lung capillary leak. Lung
EBD significantly increased in ischemic AKI and bilateral
nephrectomy compared with sham operation (Figure 4).
Wild-type and IL-6-deficient mice (IL-6/) develop AKI at
similar rates after ischemic AKI or bilateral nephrectomy
To test the hypothesis that lung injury after AKI is
interleukin-6 (IL-6) dependant, IL-6/ mice were studied.
As the peak of lung injury in wild-type mice was at 4 h, end
points of lung injury were examined 4 h after ischemic AKI
and bilateral nephrectomy in IL-6/ mice.
To determine the rate of development of renal dysfunction
in wild-type compared with IL-6/ mice, serum creatinine
was measured at baseline and at 4 and 24 h after sham
operation, ischemic AKI, or bilateral nephrectomy. Serum
creatinine significantly increased 4 and 24 h after ischemic
AKI or bilateral nephrectomy in wild-type and IL-6/ mice
(Figure 5). There was no significant difference in the
timing or degree of renal dysfunction between wild-type
and IL-6/ mice. Likewise, blood urea nitrogen was similar
in wild-type and IL-6/ mice after sham operation,
ischemic AKI and bilateral nephrectomy (data not shown).
Serum IL-6 increases after ischemic AKI and bilateral
nephrectomy in wild-type mice
Serum IL-6 was measured by ELISA 4 h after sham operation,
ischemic AKI, and bilateral nephrectomy in wild-type and
IL-6/ mice. IL-6 in wild-type mice was significantly
elevated after both ischemic AKI and bilateral nephrectomy
compared with sham and was not detected in IL-6/ mice
(Figure 6).
Lung injury after AKI in IL-6/ mice
Increased lung MPO activity demonstrated after ischemic
AKI and bilateral nephrectomy in wild-type mice was
significantly attenuated in IL-6/ mice (Figure 7a). To
determine whether improved MPO activity in IL-6/ mice
was associated with improved capillary leak, lung content of
EBD was determined in wild-type and IL-6/mice 4 h after
Sham operation, 4 h Ischematic AKI, 4 h
Bilateral nephrectomy, 4 h
a b
c
Figure 3 | Lung histology after ischemic AKI and bilateral
nephrectomy. Pulmonary histology (hematoxylin and eosin,
 40) is normal 4 h after (a) sham operation in wild-type mice.
Pulmonary histology 4 h after (b) ischemic AKI and (c) bilateral
nephrectomy in wild-type mice is characterized by septal edema
and neutrophil infiltration. Figures are representative of at least
three separate experiments.
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Figure 4 | Pulmonary capillary leak after ischemic AKI and
bilateral nephrectomy. Evans blue dye (EBD) was administered
via tail vein injection, and lung EBD content (an indicator of
pulmonary capillary leak) was determined at baseline and at 4 h
after sham operation, ischemic AKI, and bilateral nephrectomy in
wild-type mice. EBD content increased after ischemic AKI and
bilateral nephrectomy, indicating increased capillary leak (N¼ 4
for baseline, 7 for sham operation, 6 for ischemic AKI, and 10 for
bilateral nephrectomy).
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Figure 5 | Time course of renal failure after ischemic AKI and
bilateral nephrectomy in wild-type (WT) and IL-6-deficient
(IL-6/) mice. Serum creatinine was determined at baseline and
at 4 and 24 h after sham operation (Sham), ischemic AKI (IAKI), and
bilateral nephrectomy (BNx). Serum creatinine was unchanged
following sham operation, but was increased at 4 and 24 h after
ischemic AKI and bilateral nephrectomy. No significant difference
in serum creatinine was observed between WT and IL-6/ mice
at any time point (N¼ 3–6). *Po0.01 IAKI vs Sham, **Po0.001
IAKI vs Sham, wPo0.001 BNx vs Sham.
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ischemic AKI and bilateral nephrectomy. Reduced lung EBD,
indicating reduced capillary leak, occurred in IL-6/ mice
after both ischemic AKI and bilateral nephrectomy (Figure 7b).
Lung chemokines after AKI in IL-6/ mice
To investigate whether decreased lung MPO activity observed
in IL-6/ mice was associated with altered lung chemokine
expression, the neutrophil chemokines KC and MIP-2 were
measured by ELISA in lung tissue 4 h after sham operation,
ischemic AKI, and bilateral nephrectomy in wild-type and
IL-6/ mice. Lung KC was significantly reduced in IL-6/
compared with wild-type mice after ischemic AKI and
bilateral nephrectomy (Figure 8a). In contrast, no differences
in lung MIP-2 were found in IL-6/ compared with wild-
type mice after AKI (Figure 8b).
Lung injury after AKI in wild-type mice administered with
anti-IL-6 antibody
To test whether an intervention targeting IL-6 would
ameliorate lung injury after AKI, 20 mg anti-IL-6 antibody
vs IgG control was administered to wild-type mice 1 h before
surgery, at the time of clamp removal (ischemic AKI) or
nephrectomy (bilateral nephrectomy) and 1 h following
surgery (60 mg total). Administration of anti-IL-6 antibody
to wild-type mice significantly reduced pulmonary MPO
activity 4 h after bilateral nephrectomy; a trend toward
decreased MPO activity was observed in ischemic AKI
(Figure 9a). Additionally, increases in lung KC after ischemic
AKI and bilateral nephrectomy were significantly attenuated
in wild-type mice treated with anti-IL-6 antibody vs IgG
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Figure 6 | Serum IL-6 after ischemic AKI and bilateral
nephrectomy. Serum IL-6 was determined 4 h after sham
operation, ischemic AKI, and bilateral nephrectomy in wild-type
(WT) and IL-6-deficient (IL-6 /) mice. IL-6 was elevated after
both ischemic AKI and bilateral nephrectomy compared
with sham (N¼ 3–5). As expected, IL-6 was not detected in
IL-6/ mice (N¼ 3–5).
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Figure 7 | Lung injury after AKI in IL-6/ mice. (a) Lung MPO
activity (a marker for neutrophils) was increased 4 h after ischemic
AKI and bilateral nephrectomy in wild-type (WT) mice, and this
increase was ameliorated in IL-6-deficient (IL-6/) mice
(N¼ 4–6). (b) Lung EBD content (a marker of capillary leak) was
attenuated in IL-6/ mice with ischemic AKI or bilateral
nephrectomy compared with wild type (N¼ 5–9).
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Figure 8 | Lung chemokines after AKI in IL-6/ mice. Lung KC
and MIP-2 were measured by ELISA 4 h after ischemic AKI and
bilateral nephrectomy. (a) Lung KC was significantly reduced in
IL-6-deficient (IL-6/) mice compared with wild-type (WT) after
ischemic AKI and bilateral nephrectomy (N¼ 3–6). (b) Lung MIP-2
was similar in IL-6-deficient and wild-type mice after ischemic
AKI and bilateral nephrectomy (N¼ 4–6).
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control (Figure 9b); no difference in lung MIP-2 was noted
(data not shown). To determine if the improvement in lung
injury was independent from effects of anti-IL-6 antibody on
kidney function, serum creatinine was measured 4 h after
ischemic AKI or bilateral nephrectomy and was found to be
similar in mice administered with perioperative anti-IL-6
antibody vs IgG control (Figure 9c).
Lung MPO activity after intravenous administration of IL-6 to
wild-type mice
To test whether intravenous administration of IL-6 could
directly cause lung injury, 1mg of recombinant murine IL-6
was administered by tail vein injection to wild-type mice
(no surgery), which resulted in increased pulmonary
MPO activity at 4 h compared with vehicle administration
(Figure 10a). Neither KC nor MIP-2 was detected in lungs of
wild-type mice 4 h following the intravenous administration
of IL-6 (data not shown). Serum creatinine 4 h after
intravenous administration of IL-6 was similar to creatinine
in mice administered with vehicle (saline) (Figure 10b).
Serum cytokines in IL-6/ mice
A total of 22 serum cytokines/chemokines (IL-1a, IL-1b,
IL-2, IL-3, IL-4, IL-5, IL-9, IL-12(p40), IL-12(p70), IL-13,
IL-17, IL-19, MIP-1a, MIP-1b, granulocyte colony-stimulat-
ing factor, granulocyte macrophage colony-stimulating
factor, KC, monocyte chemotactic protein-1, eotaxin, regu-
lated on activation normal T cell expressed and secreted,
tumor necrosis factor-a, interferon-g) were measured 4 h
after sham operation, ischemic AKI, and bilateral nephrect-
omy in wild-type and IL-6/ mice. KC was significantly
reduced in IL-6/ mice compared with wild type after both
ischemic AKI and bilateral nephrectomy (Figure 11). IL-12
(p40) was significantly reduced in IL-6/ mice compared
with wild type after bilateral nephrectomy alone (data not
shown). No significant differences between wild-type and
IL-6/ mice after ischemic AKI or bilateral nephrectomy
were noted in the remaining 20 serum cytokines/chemokines
measured (data not shown).
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Figure 9 | Lung MPO activity and KC after administration of
anti-IL-6 antibody to wild-type mice in AKI. (a) Pulmonary
MPO activity 4 h after bilateral nephrectomy was decreased with
anti-IL-6 antibody treatment. (b) The increase in lung KC 4 h
after ischemic AKI or bilateral nephrectomy was significantly
attenuated in wild-type (WT) mice administered with anti-IL-6
antibody vs IgG control (N¼ 6). (c) Serum creatinine was similar in
wild-type mice treated with anti-IL-6 antibody or IgG control
4 h after ischemic AKI and bilateral nephrectomy (N¼ 5–7).
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Figure 10 | Lung MPO activity after intravenous
administration of IL-6 to wild-type mice. A total of 1 mg of
recombinant murine IL-6 vs vehicle (sterile PBS) was administered
via tail vein injection to wild-type (WT) mice. (a) At 4 h, lung MPO
activity was significantly increased in mice administered with IL-6
vs vehicle. (b) Serum creatinine was not increased in wild-type
mice 4 h after the intravenous administration of IL-6 (N¼ 5).
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Figure 11 | Serum KC in IL-6-deficient mice. A total of 22 serum
cytokines/chemokines were measured 4 h after sham operation,
ischemic AKI, and bilateral nephrectomy in wild-type (WT) and
IL-6-deficient (IL-6/) mice. Serum KC, a neutrophil chemokine,
was significantly decreased after ischemic AKI and bilateral
nephrectomy in IL-6-deficient mice (N¼ 3–6).
Kidney International (2008) 74, 901–909 905
CL Klein et al.: Interleukin-6 in acute kidney injury o r i g i n a l a r t i c l e
DISCUSSION
Acute kidney injury is an independent contributor to
mortality27–30 regardless of degree of renal impairment.27,29,31
Interventions to enhance kidney recovery in patients with
AKI have been largely unsuccessful, limiting treatment to
supportive measures such as dialysis. An attractive approach
to reducing the significant morbidity and mortality asso-
ciated with AKI is to specifically target the deleterious
systemic complications that result from AKI.
Clinical human and experimental animal studies demon-
strate that pulmonary dysfunction is an important systemic
consequence of AKI. Respiratory failure requiring mechanical
ventilation develops more frequently in patients with AKI,2
and patients with AKI have impaired ability to wean from the
ventilator.3 The need for mechanical ventilation is an
independent predictor of mortality in patients with AKI,
with mortality rates of 81% in those requiring vs 29% in
those not requiring mechanical ventilation.1 Animal models
of AKI including ischemic AKI and bilateral nephrectomy
have been utilized to study the pulmonary effects of AKI.
Although anti-inflammatory therapies reduce lung injury
after AKI in rodents,5,8 specific mediators of lung injury after
AKI have not been identified. In this study, we found that
IL-6 contributes to lung injury after AKI.
Multiple independent investigators have demonstrated
that lung injury occurs after ischemic AKI or bilateral
nephrectomy in rodents, characterized by increased interstitial
leukocytes,5,8,10 lung MPO activity,5,8 BAL fluid cellularity,10
pulmonary edema,5 and capillary leak as measured by either
Evans blue dye6,10 or BAL fluid protein.5 Importantly, these
lung findings are similar to clinical and autopsy studies in
patients who demonstrate lung injury consisting of pulmonary
edema and leukocyte infiltration after AKI.32–34
The study of lung injury following AKI in rodents has
been limited to few time points;5,6,8–11 therefore, we
examined multiple early time points after both ischemic
AKI and bilateral nephrectomy to detect the onset of injury.
We found that increased lung MPO activity, neutrophil
infiltration, septal edema, and capillary leak occurred as early
as 4 h after ischemic AKI as well as bilateral nephrectomy.
This corroborates the findings of Deng et al.,8 who reported
lung injury 4 h after ischemic AKI. The use of the ischemic
AKI model is clinically relevant, as half of the cases of AKI in
hospitalized patients are due to ischemia. However, as lung
injury occurs following ischemia/reperfusion injury of other
organs, the bilateral nephrectomy model has been employed
to examine the systemic effects of renal failure without
ischemia. We confirm previous reports that pulmonary
injury also occurs following bilateral nephrectomy5,10,11,18
and demonstrate that timing of lung injury following
bilateral nephrectomy appears to parallel that observed in
ischemic AKI despite a recent report that the lung genomic
response is strikingly different in these two models.7
As lung injury after AKI is characterized by lung neutrophil
infiltration, and neutrophils are key pathogenic mediators of
ALI, we examined the effect of AKI on potential mediators of
neutrophil recruitment including the CXC neutrophil chemo-
kines KC and MIP-2, as well as the adhesion molecules ICAM-
1 and VCAM-1. Lung KC and MIP-2 were significantly
increased as early as 2 h after AKI, preceding the peak in lung
MPO activity and histological injury observed at 4 h. Increased
lung8 and cardiac35 ICAM-1 mRNA 4 h after ischemic AKI
has been reported. However, we found that although ICAM-1
and VCAM-1 were present in lung following ischemic AKI and
bilateral nephrectomy, protein levels in the AKI groups did not
differ from that expressed constitutively. Although lung
protein expressions of ICAM-1 and VCAM-1 were not altered
by AKI, this does not exclude these adhesion molecules as
important mediators of lung neutrophil recruitment. Indeed,
anti-ICAM-1 antibody administration reduced cardiac neutro-
phil recruitment following ischemic AKI.35
The signal(s) arising from AKI that results in increased
pulmonary capillary leak and lung neutrophil recruitment,
potentially via an effect on neutrophil chemokines, has not
been identified. We have previously reported that serum
cytokine profiles are different after ischemic AKI and bilateral
nephrectomy;5 however, serum IL-6 is elevated after both
ischemic AKI and bilateral nephrectomy in mice. Remark-
ably, significant increases in serum IL-6 are also observed in
hospitalized patients with AKI,19 ALI, and adult respiratory
distress syndrome21,36 and are predictive of mortality.
Neutrophil recruitment in various inflammatory models
has been shown to be facilitated by IL-6 using IL-6-deficient
mice and antibodies against IL-6 and its receptors.37,38 Given
this background, we hypothesized that IL-6 plays a role in
AKI-mediated lung injury. In this study, we demonstrate that
IL-6 contributes to lung injury after AKI, as IL-6-deficient
mice as well as wild-type mice administered with anti-IL-6
antibodies have decreased lung MPO activity and reduced
capillary leak after AKI.
We determined that strategies targeting IL-6 are associated
with reduced lung KC, but not MIP-2, after AKI. In addition,
22 cytokines/chemokines were measured in the serum of
IL-6-deficient mice after AKI and only KC was significantly
reduced after both ischemic AKI and bilateral nephrectomy.
Previous studies have demonstrated that serum KC is increa-
sed after ischemic AKI in mice.5,39 As has been demonstrated
with IL-6, IL-8 (a human analog of KC) is elevated in the
serum of patients with AKI and ALI,19,36 elevated in the BAL
fluid of patients with ALI,20 and predictive of complications
and mortality in AKI and ALI.19,21 Previous studies have
suggested a link between IL-6 and IL-8. In a murine model of
inflammation, impaired neutrophil accumulation in IL-6-
deficient mice was reversed with the administration of IL-8.37
Furthermore, IL-6-dependant endothelial cell production of
KC has been described.37,40
In a recent study, functional genomic analysis demon-
strated increased IL-6 signaling effects in the lung after ische-
mic AKI.41 IL-6 signaling requires a specific IL-6 receptor
(IL-6R) as well as a ubiquitously expressed signal-transducing
protein, gp130. IL-6 signaling can occur in cells expressing
the transmembrane IL-6R, but can also occur in cells lacking
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the membrane-bound IL-6R in a process termed as trans-
signaling. In trans-signaling, IL-6 binds to circulating soluble
IL-6 receptor (sIL-6R) and the IL-6/sIL-6R complex binds to
membrane bound gp130. Endothelial cells lack membrane-
bound IL-6R; however, endothelial cell production of KC in
response to IL-6 trans-signaling has been reported.37,40
Increased serum sIL-6R in mice with HgCl2-induced AKI
was recently reported,42 and sIL-6R is increased in patients
with chronic renal failure.43 As alveolar macrophages express
the IL-6 receptor, they are an alternative potential source of
lung KC in response to increased circulating IL-6.
Other investigators have reported renal protection after
ischemic AKI in IL-6-deficient mice.44 One could question
whether the improvement in AKI-mediated lung injury
achieved using methods targeting IL-6 is simply due to
reduced kidney injury. We demonstrate that IL-6 contributes
to lung injury independent of its potential effects on kidney
function, as no difference in the degree of renal dysfunction
after ischemic AKI was detected in IL-6-deficient mice or
wild-type mice treated with anti-IL-6 antibodies compared
with controls. As renal function is eliminated entirely after
bilateral nephrectomy, the protection against lung injury in
this model cannot be due to an effect on the kidney.
The use of the bilateral nephrectomy model also illustrates
other important effects of renal failure independent of renal
ischemia. The kidney itself can be a source of IL-6 after
ischemia/reperfusion injury;44 however, the elevation in
serum IL-6 after bilateral nephrectomy indicates that the
kidney is not the major source of increased IL-6 after AKI. As
the kidney has been demonstrated to contribute to IL-6
clearance,5,45 increased serum IL-6 after AKI likely results
from renal and extrarenal IL-6 production combined with
reduced renal IL-6 elimination.
In conclusion, we identify IL-6 as an important con-
tributor to lung injury after AKI. As inflammatory serum
cytokines have been shown to be elevated and predictive of
mortality in critically ill AKI patients, anti-inflammatory
strategies including cytokine removal via renal replacement
modalities have been explored in the hopes of improving
morbidity and mortality. These strategies are nonspecific,
however. By elucidating direct pathogenic effects of particular
cytokines, targeted therapies can be designed. Multiple
clinical studies of patients with AKI and ALI have
consistently demonstrated significant elevations in IL-6 and
IL-8, which are predictive of mortality, but have not revealed
a direct role of IL-6 and IL-8 in kidney and/or lung injury.
We demonstrate that IL-6 contributes to AKI-mediated lung
injury, potentially via an effect on lung production of KC.
Importantly, increased serum IL-6 and lung KC after AKI
precedes detectable lung injury; therefore, a therapeutic
window for specific cytokine-directed therapies may exist. We
demonstrate that administration of anti-IL-6 antibody was
associated with reduced lung KC and improved lung injury
after AKI. Therefore, specific therapies targeting IL-6 or KC
merit further investigation as potential strategies to reduce
the significant mortality associated with AKI and ALI.
MATERIALS AND METHODS
Animals
Eight- to ten-week-old male C57BL/6 mice (wild-type) and IL-6-
deficient mice backcrossed over eight generations on a C57BL/6
background were used (Jackson Labs, Bar Harbor, ME, USA). Mice
were maintained on a standard diet and water was made freely
available. All experiments were conducted with adherence to the
NIH Guide for the Care and Use of Laboratory Animals. The animal
protocol was approved by the Animal Care and Use Committee of
the University of Colorado (Protocol no. 81102007(06)1D).
Surgical protocol
Three surgical procedures were performed as described previously:5
(1) sham operation, (2) ischemic AKI, and (3) bilateral nephrect-
omy. Mice were anesthetized with IP Avertin (2,2,2-tribromoetha-
nol: Aldrich, Milwaukee, WI, USA), a midline incision was made,
and the renal pedicles identified. For ischemic AKI, pedicles were
clamped for 22 min. The bilateral renal pedicle clamp model is
established in our laboratory.46,47 After clamp removal, kidneys were
observed for restoration of blood flow by the return to their original
color. The abdomen was closed in one layer. Sham surgery consisted
of the same procedure except that clamps were not applied. For
bilateral nephrectomy, renal pedicles were tied off with suture and
then cut distally. The ureters were pinched off with forceps and the
kidneys removed.
Serum blood urea nitrogen and creatinine measurement
Serum was collected as described previously.5 Blood urea nitrogen
and creatinine were measured using an autoanalyzer (Beckman
Instruments, Fullerton, CA, USA).
Serum IL-6 measurement
Serum IL-6 was measured by ELISA according to assay instructions
(R&D Systems, Minneapolis, MN, USA).
Flow cytometry determination for serum cytokines
Serum IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-9, IL-12(p40),
IL-12(p70), IL-13, IL-17, IL-19, MIP-1a, MIP-1b, granulocyte
colony-stimulating factor, granulocyte macrophage colony-stimulat-
ing factor, KC, monocyte chemotactic protein-1, eotaxin, regulated
on activation normal T cell expressed and secreted, tumor necrosis
factor-a, and interferon-g were determined using a bead-based
multiplex cytokine kit (Bio-Rad, Hercules, CA, USA) in conjunction
with flow-based protein detection and the Luminex LabMAP
multiplex system (Luminex, Austin, TX, USA) according to the
manufacturer’s directions (detection limit for each cytokine¼
1.95 pg/ml).
Tissue processing of lungs for histology
The right hilum was tied off, the right lobes removed, rinsed
with PBS and frozen in liquid nitrogen. The left lung was expanded
with 0.5% low melting agarose at a constant pressure of 25 cm
H2O, allowing for homogenous expansion of lung parenchyma
as described previously,48 removed, fixed in 10% formalin for 24 h,
and paraffin-embedded.
Lung neutrophils
Five-micrometer sections of paraffin-embedded lung tissue were
stained with hematoxylin and eosin using standard protocols.
Neutrophils were counted on the basis of morphological criteria; at
least 50 high-powered fields ( 40) were counted per slide.
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Lung KC and MIP-2
Frozen lung was prepared for ELISA as described previously.5
Supernatants were analyzed for protein content using a Bio-Rad
DC protein assay kit (Hercules, CA, USA). KC and MIP-2 were
determined by ELISA (R&D Systems, Minneapolis, MN, USA).
Evans blue dye
A total of 250 ml of EBD (5 mg/ml) was injected via tail vein 1 h
before killing. Lungs were perfused with 5 ml PBS via the right
ventricle to remove EBD within the vasculature, excised, weighed,
and homogenized in 2 ml formamide. The homogenate was
incubated in a 37 1C water bath overnight, then centrifuged at
10,000 g for 30 min. The optical density of supernatant was
determined at 620 nm, and EBD concentration was calculated
against a standard curve (mg EBD per gram of lung tissue).
MPO activity
One-fourth lung was used to determine MPO activity as described
previously.5
ICAM-1 and VCAM-1 immunoblotting
Frozen lung was homogenized in radioimmunoprecipitation assay
buffer with protease inhibitor; western blotting was performed as
described previously.49 Goat anti-murine ICAM-1 polyclonal anti-
body (R&D Systems, Minneapolis, MN, USA; 1:2000) or rat anti-
murine VCAM-1 monoclonal antibody (R&D Systems; 1:1000) were
used.
Anti-IL-6 antibody administration
A total of 20 mg anti-IL-6 antibody vs IgG control (eBioscience, San
Diego, CA, USA) was administered to wild-type mice by tail vein
injection 1 h before surgery, intraperitoneally at the time of clamp
removal (ischemic AKI) or nephrectomy (bilateral nephrectomy)
and intraperitoneally 1 h following surgery (60 mg total).
IL-6 administration
A total of 1mg recombinant murine IL-6 in sterile PBS (R&D
Systems) was administered by tail vein injection to wild-type mice.
Statistical analysis
Data were analyzed by one-way analysis of variance comparing the
three conditions (sham operation, ischemic AKI, and bilateral
nephrectomy) at each time point. If significant F-statistic from
analysis of variance existed, this test was followed by Dunnett
post hoc multiple comparison procedure with sham operation as the
control group. For all other comparisons, Student’s t-test was used.
A P-value of o0.05 was considered as statistically significant.
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